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During the last decades, the clinical and research interest in atherosclerosis has been mostly focused on coronary arteries. After the publications
of the European Society Guidelines and AHA/ACC Guidelines on Peripheral artery diseases, and of the Registry REduction in Atherothrombosis
forContinuedHealthRegistry, therehasbeenan increased interest in atherosclerosisof the lowerextremityarteries and itspresence inmultifocal
disease. However, awareness in the general population and the medical community of non-coronary artery diseases, and of its major prognostic
implications remain relatively low. The aim of this general review stemming out of an ESC Working Group on Peripheral Circulation meeting in
2011 is to enhance awareness of this complex disease highlighting the importance of the involvement of atherosclerosis at different levels with
respect to clinical presentation, diagnosis, and co-existence of the disease in the distinct arterial territories. We also emphasize the need of an
interdisciplinary approach to face the broad and complex spectrum of multifocal disease, and try to propose a series of tentative recommenda-
tions and measures to be implemented in non-coronary atherosclerosis.
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Introduction
There is an increased interest among the medical community fornon-
coronary atherosclerosis. The most important recent initiatives in
this field have been the new ESC Guidelines on the diagnosis and
treatment of peripheral artery diseases,1 the ACC/AHA Practice
Guidelines in management of patients with peripheral artery
disease,2,3 the Trans-Atlantic Inter-Society Consensus for the Man-
agement of Peripheral Arterial Disease (TASC I and II),4,5 which all
have established important educational, clinical, and research goals
for the near future.
The pivotal results of several epidemiological studies—among
others—the Basel, and the Ankle-Brachial Index Collaboration
study6,7 have also highlighted this interest, with the former demon-
strating as early as the 60s the poor prognosis of patients with
lower extremity artery disease (LEAD). More recently, the GetABI
and the Registry Reduction in Atherothrombosis for Continued
Health Registry (REACH)8,9 have highlighted the role of atheroscler-
osis as a systemic disease with manifestations in multiple vascular
beds, and indicated that these patients have a poorer prognosis
than patients with just one territory affected9 (Figure 1). The ability
by a simple diagnostic tool as the measurement of the ankle-brachial
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index (ABI), a surrogate and objective equivalent of the presence of
LEAD, to anticipate overall cardiovascular prognosis and apply pre-
vention strategies has increased the attention for this field.8,10–12
(Figure 2) Cardiologists in fact—as elegantly demonstrated by the
initial career as specialist in vascular medicine of Andreas Gruentzig
and his invention of angioplasty13—have always been aware of the
need of a multifocal diagnostic and therapeutic approach because
atherosclerosis has a common pathogenesis, and simultaneously
affects multiple circulatory regions.
This review has been conceived following an ESC Working Group
on Peripheral Circulation meeting held in Zu¨rich in 2011 convening
20 cardiovascular specialists in peripheral circulation and athero-
sclerosis together with leading European and American cardiologists
who considered appropriate, 3 years after publication of the ESC
guidelines, to reinforce this relevant problem since its knowledge in
cardiology community tends to be low. It focuses the attention on
atherosclerosis affecting the different non-coronary arterial territor-
ies, from the upper limbs arteries, the extra-cranial carotid through
the thoracic and abdominal aorta, the mesenteric, renal, and lower
limbs arteries, and emphasizes the growing and often unrecognized
burden of vascular disease. Special attention is given to the issue of
multifocal atherosclerosis, and the need for an interdisciplinary man-
agement. Given the vast extension of the topic, all facets of vascular
diseases cannot be covered in detail, and some aspects go beyond the
scope of the paper, i.e. therapeutic strategies, and will not be covered
in this review. Finally, practical suggestions for clinicians and policy
makers to increase awareness on this important item, also highlight-
ing some areas of uncertainties in this field, are proposed.
Upper extremity arteries
In contrast to many other territories, overt atherosclerosis of the
upper limb arteries, including the case for the thoracic artery is rela-
tively rare since 3–4% of the general public have a subclavian stenosis
and 15–20% of patients with LEAD have it.14 Conversely, it is intri-
guing to see how the upper extremity arteries (i.e. the brachial arter-
ies) are the more convenient territory to assess non-invasively the
endothelial dysfunction, one powerful early indicator of subclinical
atherosclerosis. Endothelial dysfunction assessed by ultrasound
measurement of the brachial artery flow-mediated dilation (FMD)
after reactive hyperaemia or cold pressor test may provide prognos-
tic information even in the absence of overt atherosclerosis, antici-
pating progression of the atherosclerotic lesions in patients with
coronary artery disease, and in patients with LEAD.15 Measurement
of endothelial function has been of paramount importance for the
understanding of pathophysiology of early and late manifestations
of atherosclerosis and its complications, for determining the import-
ance of traditional and emerging risk factors of atherosclerosis as well
Figure 1 One-year cardiovascular event rates as a function of
number of symptomatic disease locations. All P-values , 0.001.
CV, cardiovascular; MI, myocardial infarction. Patients with at
least three factors but no symptoms are counted as 0, even in the
presence of asymptomatic carotid plaque or reduced ankle brachial
index. Error bars represent 95% confidence intervals (adapted from
Steg et al.9 with permission by the publisher).
Figure2 Hazard ratios for total mortality in men and women by ankle-brachial index at baseline for all studies combined in the ABI Collaboration
(adapted from Aboyans et al.12 with permission by the author and the publisher).
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as for the comprehension of the mechanisms of action of several drug
families and lifestyle changes crucial for the prevention as well as
treatment of atherosclerosis, i.e. ACE inhibitors, and statins. A low
brachial artery FMD is an independent predictor of cardiovascular
risk.16 Overall, the clinical relevance of upper limb atherosclerosis,
and the use of FMD in the clinical arena remain relatively low, since
the latter—in spite of its valid proof of concept—has not reached suf-
ficient clinical utility.
Carotid arteries
The relevance of extra-cranial cerebral artery atherosclerosis is
two-fold. From a clinical standpoint, carotid atherosclerosis is re-
sponsible for 25% of strokes with major impact on disability of
the growing older population.17– 19 From a clinical research stand-
point, carotid atherosclerosis represents an extraordinary window
to study in vivo early and late manifestations of atherosclerosis.20,21
The earliest visible manifestation of carotid artery disease is the thick-
ening of the intima-media which is detectable with high-resolution
B-mode carotid ultrasonography (Duplex US),22 a marker of early
subclinical atherosclerosis which correlates with incident vascular
outcomes, i.e. stroke and coronary heart disease. A recent
meta-analysis by Lorenz et al. showed the strong predictive value
of carotid intima-media thickness for the occurrence of cardiovascu-
lar events.20 The morphological presentation of atherosclerotic
plaques at the level of carotid arteries with a lipid core and fibrous
cap is similar but not exactly the same than those found in other vas-
cular areas.23,24 Carotid atherosclerotic plaques are associated with
embolization of superimposed thrombotic material,2,4,24,25 a phe-
nomenon which is clinically relatively less relevant at the level of cor-
onary arteries or lower limbs arteries.1– 5 It has been assumed that
the riskof embolization orcomplicationsof carotid plaques increases
in parallel with the degree of obstruction although the complexity of
the plaque probably plays an even more important role.25 The annual
risk of stroke in patients with asymptomatic carotid stenosis
(between 50 and 99%) is 1.0–3.3% with the higher incidence in
those with the more severe stenosis and more rapid progression of
stenosis.2,4,25 Patients with symptomatic carotid artery stenosis
with previous stroke have an annual recurrent stroke risk of
between 10 and 43%.23,25 However, it should be emphasized that
most of these studies22,23 have been performed before the wide-
spread use of statins, which may induce stabilization or reduction in
carotid atherosclerotic plaque.2,26 Duplex US is the standard tool
in clinical practice for detection and estimates the degree of severity
of carotid atherosclerosis.27 Duplex US allows to estimate not only
the degree of stenosis but also the extension and complexity of the
plaque lesion; echogenicity detected by Duplex US ultrasound has
been proposed to identify lesions at higher risk of spontaneous com-
plication or following invasive treatment (i.e. carotid surgeryor stent-
ing).28 Contrast-enhanced Duplex US is another emerging
application of ultrasound imaging which may allow the identification
of intraplaque neovascularisation, a further potential predictor of
plaque vulnerability.29
Spiral CT, and particularly MRI plaque imaging may add important
information on plaques composition and vulnerability-detecting
plaque rupture, intraplaque haemorrhage, and the presence of
thrombus.21,30–32 Recently, PET/CT-scan and hybrid techniques
prototypes using PET/CT and MRI seem to be promising research
tools for identifying inflammatory component of atherosclerotic
plaques.32 However, so far the use of these techniques is proposed
only to investigational purpose and are not used clinically.
Thoracic and abdominal aorta
The pathology of the aorta has several peculiar aspects. Atheroscler-
otic involvement of the thoracic ascending aorta and of the aortic
arch has been recognized as a significant source of ‘spontaneous’
cerebral and peripheral thromboembolism and may represent a dan-
gerous source of atherothrombotic embolism during diagnostic and
invasive procedures (PCI, on-pump cardiac surgery).33 Transesopha-
geal echocardiography is one of the most powerful tools to detect
mobile and complex plaques at the level of the aortic arch and of
the descending aorta.33,34
A clinically distinct feature is the athero-embolic syndrome asso-
ciated with severe aortic atherosclerosis and embolization from
ulcerated plaques. Hallmark of this syndrome is renal insufficiency,
skin lesions, blue toe(s), caused by micro-emboli associated with
transient eosinophilia.35 It can occur spontaneously, but frequently
results from arterial manipulation, such as catheter intervention
and aortotomy.36 Prognosis is poor with 1-year mortality rates
between 60 and 81%, although this high mortality may reflect selec-
tion bias due to the fact that these figuresderive from autopsystudies.
Over 70% of patients with athero-embolic syndrome present renal
function impairment and over 40% of these patients end-up with
severe renal failure needing dialysis.35,36
Aortic aneurysms have been traditionally considered a special
form of atherosclerosis, because this disorder is almost always asso-
ciated with severe atherosclerotic damage of the aortic wall, and
because it shares many of the same risk factors as obstructive athero-
sclerosis. However, this conventional view has been challenged in
recent years: basic and clinical research studies indicate that aneur-
ysms arise through pathogenic mechanisms that are distinct from
those responsible for athero-occlusive disease.37,38
Renal arteries
Haemodynamically significant renal artery stenosis (RAS) is asso-
ciated with hypo-perfusion of the renal parenchyma which induces
a series of (patho)-physiological responses, including upregulation
of the renin–angiotensin–aldosterone system followed by fluid re-
tention, reduced natriuresis, and vasoconstriction which may
end-up with perpetuation of arterial hypertension , renal fibrosis,
and renal function impairment.39,40 The recent refinement and
increasing use of diagnostic procedures such as Duplex US ultra-
sound,41 angio-CT, andmagnetic resonance42 in the older population
with diffuse atherosclerosis undergoing invasive diagnostic proce-
dures (i.e. coronary angiography) have changed the spectrum of clin-
ical presentation of RAS. Cardiologists face relatively frequently the
management of patients with multi-morbid poly-vascular patients
with uni- (or bilateral) atherosclerotic obstructive disease of the
renal arteries. These patients may present with renal with resistant
arterial hypertension, renal function deterioration, ‘flash’ pulmonary
oedema, and unstable angina.43
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Mesenteric artery
The prevalence of acute and chronic mesenteric ischaemia is low, but
its clinical relevance is high since ischaemia may be often fatal particu-
larly in cases of acute presentation.1 –5 Mesenteric ischaemia may be
caused by atherosclerosis, arterial emboli, or thrombosis as well as
several other rare pathologies affecting the mesenteric arteries
(fibro muscular dysplasia, arterial infection, aneurysms, or dissec-
tions). Acute mesenteric ischaemia is often a result of cardio-embolic
events or due to embolization following endovascular procedures.
Other causes are arterial thrombosis based on a pre-existent stenot-
ic lesion, acute aortic dissection, or hypercoagulability states. Patients
with acute mesenteric ischaemia often present with abdominal pain
out of proportion to physical findings associated with leukocytosis
and lactic acidosis, and have frequently a history of cardiovascular
disease or a recent history of cardiovascular intervention.2,44
Computer tomography is the diagnostic tool to identify thrombosis
of the proximal intestinal arteries and its consequences (intestinal
wall thickening, distension, abdominal fluid, or perforation). Chronic
intestinal ischaemia affects predominantly women. Patients often
present with postprandial abdominal pain frequently associated
with weight loss, although the absence of the typical postprandial dis-
comfort is not infrequent, making this diagnosis very challenging.44
While Duplex US is often the first row imaging method, CT (and/
or MRI) are the most adequate investigations to detect the affected
vessels causing ischaemia and its consequences. The sensitivity and
specificity for detection of mesenteric ischaemiawith newermultide-
tector CT and magnetic are for both .90%.45,46
Lower extremity arteries
Oneof the most recently re-discovered aspects of non-coronaryath-
erosclerosis is the major prognostic impact of the presence of
a symptomatic or asymptomatic atherosclerotic involvement of
the peripheral arteries of the lower limbs (LEAD).1– 5,8,47,48 The
prevalence of LEAD is high especially, in subjects over the age of 65
(Figure 3).The life expectancy of a patient with severe claudication
is ,80% at 5 years follow-up, and an additional 20% of patients
suffer of non-fatal cardiovascular events.5,48 Patients with more
moderate symptoms or asymptomatic LEAD are also at significant
higher risk to die because of cardio- or cerebrovascular complica-
tions.1–5,8,47,48 (Figure 1) In spite of this poor survival prognosis,
patients with LEAD have received until recently scant public attention,
half of claudicants being not recognized as such.1–5,9,11,49,50 Once diag-
nosed, patients with LEAD have significantly less chance of receiving
appropriate risk factor modification, statins, and antithrombotic treat-
ment than patients with coronary or cerebrovascular disease.9,11,11,50
Awareness of this condition should be promoted by the use of
simple diagnostic tools such as measurement of the ABI, in order to
detect a larger population of high-risk patients who should receive ap-
propriate cardiovascular treatment.1–5,9,11 The poor general progno-
sis of these patients contrasts with the relatively benign course of the
local disease, only 25% of patients experience symptomatic deterior-
ation, and 2–6% eventually lose the involved leg within 5 years.1–5
Critical limb ischaemia (CLI) deserves a special place in the spec-
trum of LEAD since it is a hallmarkof dismal prognosis in terms of sur-
vival (up to 45% mortality within 1 year) and limb loss.51 It is clinically
defined by the presence of rest pain or gangrene associated with
chronic ischaemia, and is usually associated with an ankle pressure
≤50 mmHg. It may develop slowly or occur with acute onset of
symptoms in patients following distal athero-embolisation or in
patients with multisegmental atherothrombosis.1– 5 It should be
clearly differentiated from acute limb ischaemia, although the latter
is also associated with risk of amputation: it follows acute arterial em-
bolism and is accompanied by acute onset of symptoms with an
obvious embolic source (atrial fibrillation, left ventricular aneurysm,
atheromatous plaque in the aorta, or mural thrombus of arterial an-
eurysm), absence of previous claudication, and the presence of
normal arterial pulses and Doppler systolic blood pressures in the
contralateral extremity.1– 5,51
From the clinical research standpoint, atherosclerosis of the lower
extremities still remains an important model to study ‘in vivo’ patho-
physiology of atherosclerosis such as the studyof arterial remodelling
52,53 and new treatment strategies as it was the case for angioplasty
which was first introduced by A. Gruentzig to treat non-coronary
atherosclerotic obstructions at the level of the lower limb arteries
before being applied to the coronary arteries.13
A further example of how peripheral vascular medicine may be
relevant to explore new cardiovascular revascularization strategies
is angiogenesis. Intensive research in this field undertaken by
J. Isner, another cardiologist interested in peripheral artery disease,
allowed new insight into the complex issue of CLI, microcirculation
and potential treatment modalities which have been relevant also
for other territories (i.e. myocardium).54,55 Through the emphasis
on the importance of a global view of multisite atherosclerosis, and
a close contact among internationalists in distinct arterial fields,
there is a steady increasing mutual influence between coronary and
non-coronary vascular specialists.
Multifocal atherosclerosis
The REACHregistryhas clearly confirmed that the presence ofmulti-
focal atherosclerosis has a major clinical and prognostic impact
Figure 3 Estimated prevalence of peripheral arterial disease in
the European Union. Estimation obtained through http://europa.
eu.int/en/comm/eurostat/eurostat.html and estimation form
GetABI study* (adapted from Diehm and Baumgartner38)**.
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(Figures 1 and 2).1–5,9 The co-coexistence of coronary artery disease
plays obviously a major prognostic role in terms of mortality.1,6
Apart from the deemed spontaneous prognosis this may be important
in those patients scheduled and undergoing vascular revascularization
procedures, although the conclusions of a recent multicentre trial in
patients scheduled for major vascular interventions did not show a sig-
nificant benefit in patients undergoing preoperative coronary evalu-
ation and revascularization (Table 1 and 2).56
The cause of the different prevalence of atherosclerosis at the
level of distinct territories is complex. Loco-regional hemodynamic
and rheological factors as a turbulent flow at bifurcations or side
branches are also important mechanisms predisposing and favouring
the progression of atherosclerotic lesions.2,4 The distribution,
predominance, and co-existence of atherosclerosis at different loca-
lizations of the arterial tree remain however frequently elusive, al-
though some clues of distribution emerge from epidemiological
series. Genetic, traditional, and/or emerging risk factors, inflamma-
tory markers, environmental and socio-economic factors all may
play an important role.1– 5,57– 59 The different prevalence of classic
risk factors in the various territories are important for both predom-
inance and prognosis: smoking is three times more likely to cause
LEAD than coronary artery disease.60 Conversely, the association
of hypertension with LEAD is lower than the association of hyperten-
sion with coronary artery disease or cerebrovascular disease.61
Indeed, patients with carotid atherosclerosis present a stronger rela-
tionship with arterial hypertension (and benefit more of antihyper-
tensive treatment) than patients with coronary atherosclerosis.62
Multifocal atherosclerosis
in patients with lower extremity
artery disease as primary
manifestation of disease
Patients with LEAD have a poor prognosis as this disease is associated
with two- to six-fold risk of coronary and cerebrovascular disease,
when compared with the normal population.1 –5,63–71 In fact, the
presenceofLEAD in itself constitutes averypotent risk factorequiva-
lent. The severity of LEAD goes hand in hand with an increased
cardio- and cerebrovascular morbidity and mortality. Patients with
more severe claudication present a higher prevalence of CAD and
CVD than those with mild symptoms, and patients presenting with
CLI, i.e. with rest pain or gangrene, will have the highest associated
cardiovascular morbidity and mortality (up to 90% incidence of
CAD and 1-year mortality ranging from 25 to 50%).1– 5,51 Cardiolo-
gists should better be aware of these figures while treating patients
with LEAD not only because of the deemed spontaneous prognosis
but also when estimating the risk of a surgical intervention. The pres-
ence of LEAD stratify the patient into a higher risk group. One-third
of patients with LEAD present coronaryartery disease on the basis of
historyandelectrocardiogramtwo-thirdson thebasisof an abnormal
stress test and up to 70% present at least single vessel disease at cor-
onary angiography. Whether a silent concomitant CAD should be
confirmed and treated by an invasive procedure depends at the
end upon the cardiac indication to coronary angiography and revas-
cularisation.56
The risk of stroke in male patients with LEAD has been reported
four to five times higher than in patients without LEAD.71 Approxi-
mately 20% of patients with LEAD have a significant carotid stenosis
detected at Duplex US ultrasound.1– 5,65,66 The severity of LEAD
seems to correlate with the severity of carotid artery stenosis.67
The presence of carotid bruits in LEAD patients should foster the
search of carotid internal stenosis, i.e. by Duplex US: subsequent
diagnostic and therapeutic strategies are driven again by the clinical
presentation and the degree of the concomitant carotid stenosis.
Multifocal involvement in patients
presenting with carotid arteries
atherosclerosis
Patients with significant carotid artery disease (i.e. stenosis . 70–
80%) are more prone to die following acute coronary syndrome
than cerebrovascular events, pointing to the high prevalence of con-
comitant coronary artery disease.72 Thus, patients with carotid
artery disease should undergo aggressive medical treatment of
their risk factors in analogy to patients with ‘lone’ coronary artery
disease.
Patients with symptomatic carotid artery atherosclerosis have per
se a 30% and 20% co-prevalence of CAD and LEAD respectively.1–3,58
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Table 1 Non-coronary atherosclerosis: co-prevalence in other territories
Affected
territory
Carotid arteries Aorta Renal arteries
Clinical
presentation
ICA < 60%
asymptomatic
ICA > 60%
asymptomatic
ICA > 70%
symptomatic
Athero-embolism Thoracic
aneurysm
Abdominal
aneurysm
Hypertension
or renal failure
Associated atherosclerosis
CAD up to 25% up to 35% .50% up to 40% .50% up to 90%
CVD .50% up to 20% .50% up to 60%
PAD up to 10% up to 20% .50% up to 30% .50% up to 60%
CAD, coronary artery disease; CVD, cerebro-vascular disease; ICA, internal carotid artery stenosis; PAD, lower limb artery disease.
Co-prevalence estimated according: Circulation 2006;113:e463–e465; Dormandy and Rutherford4; Tendera et al.1; J Vasc Surg 1994;19:668–74; Circulation 2006.
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Recent studies indicate that patients with cerebrovascular athero-
sclerosis also have simultaneous subclinical LEAD as detected by
Duplex US and the ABI.73,74 Whether and how a patient with signifi-
cant carotid artery disease should be screened for the concomitancy
of CAD remains a question of debate even in case of a planned inva-
sive surgical carotid revascularization procedure.1 – 3 The bottom line
remains that, in the presence of cerebrovascular atherosclerosis, the
concomitant involvement of other territories is not infrequent, and in
case of clinical suspicion should be actively searched by non-invasive
methods.
Patients presenting with aortic
aneurysms as primary
manifestation of disease
It is well known that patients with aortic aneurysms present with
higher prevalence of smoking, hypertension which are associated
with diffuse atherosclerosis with high cardiac and vascular co-
morbidities, i.e. coronary artery disease, heart failure, and carotid
artery, and/or LEAD. The presence of concomitant coronary athero-
sclerosis in patients undergoing abdominal (or thoracic) aneurysm
repair has been extensively studied and its prevalence depends on
the screening method (up to 50% according to the method of detec-
tion).2,3,75 The high concomitant cardiovascular co-morbidity is a
matter of major concern especially in patients needing open aortic
repair who have symptomatic coronary artery disease or decompen-
sated heart failure.1 –5,76 Conversely, in patients with stable coronary
artery disease, the risk of cardiovascular events during aortic repair
seems nowadays relatively low, obviating the need of preventive cor-
onary revascularization.56
Patients presenting with renal
atherosclerosis
Patients with unilateral and—most importantly—with bilateral renal
artery atherosclerotic obstructions have a dismal prognosis because
they probably represent a marker of the burden of global athero-
sclerosis.40 Renal function impairment in these cases seems to per-
petuate and accelerate the process of systemic atherosclerosis
which is associated in patients with chronic kidney disease with a car-
diovascular mortality of 30–50%.1,40,43,77
Comprehensive approach
Given the broad spectrum of non-coronary atherosclerosis, there is
a need for a comprehensive approach. When facing a patient with
non-coronary artery disease, one has to keep in mind the frequent
systemic feature of the disease, i.e. the potential involvement of
other territories, i.e. coronary or cerebrovascular arteries making
the cardiologist a natural player in the management of these patholo-
gies. This may especially be relevant not only for prognostic purposes
but, most importantly, in cases where revascularisation is needed in
order to plan and prioritize which territory should be firstly
treated (concomitant or staged procedures). As recently under-
scored by the 2011 ESC guidelines on Peripheral Artery Diseases
and by the NHLBI, a multidisciplinary team including specialists in car-
diovascular medicine, vascular surgery, radiology and even some-
times other fields according to the organs involved should take
care of these patients. Recently, an EU division in vascular medicine
has been officially recognized by the UE regulatory agency
(UEMS)* in Europe, and a National Institute of Health (NIH) fellow-
ship in clinical vascular medicine has been advocated in the USA**.
This speciality/fellowship includes a 2- to 3-year training period
with intensive teaching in basic, clinical, pathophysiology, non-
invasive and invasive diagnostic, prevention and therapeutic strat-
egies in vascular medicine.
Multidisciplinary boards, pending upon the local situation, may be
moreefficientwhen theseorganization models are integrated prefer-
ably into a broad cardiovascular concept, i.e. within cardiovascular
centres. Major efforts in this direction should be pursued in order
to better achieve a global management of patients with non-coronary
and coronary atherosclerosis.
*UEMS—European Union of Medical Specialists http://www.uems.
net/EU—Division of Angiology
**NHLBI Vascular Medicine Training Programme Working Group
Executive Summary http://www.nhlbi.nih.gov/Meetings/workshops/
vascular-med.htm
Economical impact of
non-coronary atherosclerosis
The results of REACH Registry—a large, international, prospective
study of stable outpatient population with either established symp-
tomatic atherothrombosis (CAD, cerebrovascular disease, or
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Table 2 Lower limb artery disease: co-prevalence in other territories
Affected territory Lower limb arteries
Clinical presentation Asymptomatic ABI <0.9 Intermittent claudication Acute limb ischaemia Chronic CLI Aneurysm
Associated atherosclerosis
CAD Up to 50% AF frequent Up to 90% Up to 50%
CVD Up to 20% .50% Up to 60% Up to 20%
ABI, ankle-brachial index; AF, atrial fibrillation, CAD, coronary artery disease; CVD, cerebrovascular disease.
Co-prevalence estimated according: J Vasc Surg 1994;19:668–74; Tendera et al.1; Circulation 2006;113:e463–e465; Dormandy and Rutherford4.
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LEAD)—have clearly indicated that symptomatic LEAD is associated
with the greatest costs when compared with coronary artery disease
and cerebrovascular disease.78,79 (Figure 4) In this registry, the
authors compared the rates of associated costs in the USA with
LEAD across patient subgroups as well as the incidence of vascular-
related hospitalizations. Patients with symptomatic LEAD at
enrolment were defined on the basis of presence of intermittent
claudication with an ABI, 0.90 or a history of previous lower
limb revascularization (or amputation). Asymptomatic LEAD was
defined when ABI < 0.90 in the absence of symptoms. A total of
2396 (9.3%) had symptomatic and 213 (0.8%) had asymptomatic
LEAD at baseline were considered for the cost analysis. Based on
the results of the American REACH cohort and of the 2004 US
census data, the total annual costs associated with vascular hospita-
lizations in patients with LEAD would excess $21 billion. Similar
results and cost extrapolations have been observed in several Euro-
pean cohorts of the REACH Registry where 2-year hospitalization
costs were highest for patients with LEAD.80 These data emphasize
the need for an early and aggressive identification, prevention, and
treatment of LEAD which is clearly underdiagnosed and under-
treated. Several further studies have underlinedhow LEAD is respon-
sible of a major proportion of the burden on healthcare systems
beyond from indirect costs, as those related to lost productivity.81
All these costs could potentially be reduced, i.e. through long-term
prevention, when the disease would be recognized at an earlier
stage, although such long-term prevention is expensive on its
own.82 Therefore, there is a need for further prospective studies
on cost efficacy of long-term preventions strategies in the setting of
non-coronary atherosclerosis, and in patients with LEAD which
may allow to draw more solid cost-efficacy conclusions. The same
holds also true in the field of cost–benefit analysis of revasculariza-
tion procedures in LEAD where there is also a need of prospective
studies including long-term standardized evaluation of patient-
centric results, and re-intervention outcomes as reported in a
recent a systematic review of the Mayo clinic on economic evaluation
of LEAD revascularization procedures.83
Areas of uncertainty
Compared with CAD where a huge amount of prospective data
based on RCTs has been generated during the last three decades
on diagnostic-, preventive-, and therapeutic strategies, clinical re-
search in non-coronary and multisite atherosclerosis—as reported
in Table 3 and 4—has suffered of a relatively limited interest, and
large RCTs are generally lacking. This may be related to the frequent
involvement of multiple arterial districts preventing to focus in detail
on each arterial area. Thus, several data on management of LEAD and
on carotid artery disease are frequently extrapolated from results
derived from CAD. Although the relevance of traditional risk
factors has been evaluated in patients with LEAD, the role of emer-
gent risk factors and of drug prevention has been limited studied in
large prospective studies. We also have poor data on the causes of
different behaviour in progression of atherosclerosis among the dis-
tinct arterial sites.
Data regarding multisite atherosclerosis are lacking: the usefulness
of carotid revascularization in asymptomatic patients with .80%
Figure 4 Data from the One-Year Costs in Patients With a
History of or at Risk for Atherothrombosis in the United States
Costs across patient subgroups defined according to specific arter-
ial bed(s) affected and the number of affected arterial beds. Total
costs per patient (mean, with 95% confidence interval) adjusted
for covariates by presence of multiple risk factors only and
number of diseased vascular beds (cerebrovascular, coronary,
and peripheral). Hosp, hospitalization; MRFs, multiple risk factors.
There is a consistent increase in costs with each additional diseased
arterial bed. (Adapted from Circulation Outcomes 2008;1:
38–45).79
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Table 3 Key messages by the panelists
Key messages
Prevalence of LEAD in subjects .60 years is higher than actually
perceived by the medical community
Prognosis in LEAD (independent of symptoms) is poor
Multivascular atherosclerosis is frequent in the presence of LEAD
and is associated with high morbidity and mortality
Patients with LEAD and multivascular disease receive insufficient
primary and secondary prevention
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Table 4 Measures to be implemented in non-coronary
atherosclerosis
Measures to be implemented in non-coronary atherosclerosis
Further increase awareness in the cardiology community and in the
public of the clinical and prognostic relevance of LEAD
Increase awareness of the importance of multivascular disease
Females with LEAD should receive more attention
The use of ABI as a diagnostic and prognostic tool should be encouraged
among GPs and specialists
RCTs and Surveys on LEAD and multisite atherosclerosis are needed
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internal carotid stenosis before CABG remains uncertain. The
optimal timing (staged or synchronous), and the method for
carotid revascularization (carotid endarterectomy or stenting) in
patients undergoing CABG have not yet been clearly identified.
Conclusions
Non-coronary atherosclerosis includes a large spectrum of disease
with distinct manifestations at different vascular locations; it may
occur in isolated form or—more frequently—simultaneously at
various sites. Associated CAD is frequent especially in the case of
lower limb atherosclerosis, which is a powerful predictor of mortal-
ity, hospitalizations, and costs. Awareness of the disease and active
screening for non-coronary atherosclerosis using simple diagnostic
tools are essentials for the detection of disease. Once diagnosed
efforts should be made for a holistic management aiming at treat-
ing and preventing the whole spectrum of the disease and their
complications.2
This review by the ESC Working Group on Peripheral Circulation
and by the panellists of the 2011 Zu¨rich meeting suggest some tenta-
tive strategies (Table 3, 4, 5) in order to further improve management,
and to increase visibility of non-coronary atherosclerosis. The panel-
lists propose several tentative measures to be implemented in the
field non-coronary atherosclerosis and to increase awareness of
this disease complex (Tables 4 and 5). The use of ABI as a diagnostic
and prognostic tool should be more encouraged among GPs and spe-
cialists; females with LEAD should receive more attention; rando-
mized clinical trials, surveys, and registries on LEAD and multisite
atherosclerosis should also be encouraged. Awareness of the
disease should be increased through public campaigns at European,
national, and community levels. The medical communities should
be sensitized through the existing guidelines on peripheral arter-
ies,1– 5 and more emphasis on LEAD during graduate and postgradu-
ate teaching.
Conflict of interest: none declared.
References
1. Tendera M, Aboyans V, Bartelink ML, Baumgartner I, Cle´ment D, Collet JP,
Cremonesi A, De Carlo M, Erbel R, Fowkes FG, Heras M, Kownator S, Minar E,
Ostergren J, Poldermans D, Riambau V, Roffi M, Ro¨ther J, Sievert H, van
Sambeek M, Zeller T. ESC guidelines on the diagnosis and treatment of peripheral
artery diseases: document covering atherosclerotic disease of extracranial carotid
and vertebral, mesenteric, renal, upper and lower extremity arteries. The Task
Force on the Diagnosis and Treatment of Peripheral Artery Diseases of the Euro-
pean Society of Cardiology (ESC). Eur Heart J 2011;32:2851–2906.
2. Hirsch AT, Haskal ZJ, Hertzer NR, Bakal CW, Creager MA, Halperin JL, Hiratzka LF,
Murphy WR, Olin JW, Puschett JB, Rosenfield KA, Sacks D, Stanley JC, Taylor LM Jr,
White CJ, White J, White RA, Antman EM, Smith SC Jr, Adams CD, Anderson JL,
Faxon DP, Fuster V, Gibbons RJ, Halperin JL, Hiratzka LF, Hunt SA, Jacobs AK,
Nishimura R, Ornato JP, Page RL, Riegel B. ACC/AHA 2005 guidelines for the man-
agement of patients with peripheral arterial disease (lower extremity, renal, mesen-
teric, and abdominal aortic): executive summary a collaborative report from the
American Association for Vascular Surgery/Society for Vascular Surgery, Society
for Cardiovascular Angiography and Interventions, Society for Vascular Medicine
and Biology, Society of Interventional Radiology, and the ACC/AHA Task Force
on Practice Guidelines. J Am Coll Cardiol. 2006;47:1239–1312.
3. Anderson JL, Halperin JL, Albert NM, Bozkurt B, Brindis RG, Curtis LH, Demets D,
Guyton RA, Hochman JS, Kovacs RJ, Ohman EM, Pressler SJ, Sellke FW, Shen WK.
Management of patients with peripheral artery disease (Compilation of 2005 and
2011 ACCF/AHA Guideline Recommendations): a report of the American
College of Cardiology Foundation/American Heart Association Task Force on Prac-
tice Guidelines. J Am Coll Cardiol. 2013;6:1555–1570.
4. Dormandy JA, Rutherford RB. Management of peripheral arterial disease (PAD).
TASC Working Group. TransAtlantic Inter-Society Consensus (TASC I). J Vasc
Surg 2000;31:S1–S296.
5. Norgren L, Hiatt WR, Dormandy JA, Nehler MR, Harris KA, Fowkes FG,
Caporusso J, Durand-Zaleski I, Komori K, Lammer J, Liapis C, Novo S, Razavi M,
Robbs J, Shaper N, Shigematsu H, Sapoval M, White C, White J, Clement D,
Creager M, Jaff M, Mohler E III, Rutherford RB, Sheehan P, Silesen H, Rosenfield K.
Inter-Society Consensus for the Management of Peripheral Arterial Disease
(TASC II). J Vasc Surg 2007;45(1 Suppl.):S5–S67.
6. Widmer LK, Greensher A, Kannel WB. Occlusion of peripheral arteries: a study of
6,400 working subjects. Circulation 1964;30:836–842.
7. Ankle Brachial Index Collaboration, Fowkes FG, Murray GD, Butcher I, Heald CL,
Lee RJ, Chambless LE, Folsom AR, Hirsch AT, Dramaix M, deBacker G,
Wautrecht JC, Kornitzer M, Newman AB, Cushman M, Sutton-Tyrrell K,
Fowkes FG, Lee AJ, Price JF, d’Agostino RB, Murabito JM, Norman PE, Jamrozik K,
Curb JD, Masaki KH, Rodrı´guez BL, Dekker JM, Bouter LM, Heine RJ, Nijpels G,
Stehouwer CD, Ferrucci L, McDermott MM, Stoffers HE, Hooi 62 JD,
Knottnerus JA, Ogren M, Hedblad B, Witteman JC, Breteler MM, Hunink MG,
Hofman A, Criqui MH, Langer RD, Fronek A, Hiatt WR, Hamman R, Resnick HE,
Guralnik J, McDermott MM. Ankle brachial index combined with Framingham risk
score to predict cardiovascular events and mortality: a meta-analysis. JAMA 2008;
300:197–208.
8. Diehm C, Lange St, Darius H, Pittrow D, von Stritzky B, Tepohl G, Haberl RL,
Allenberg JR, Dasch B, Trampisch HJ. Association of low ankle brachial index with
high mortality in primary care. Eur Heart J 2006;27:1743–1749.
9. Steg G Ph, Bhatt DL, Wilson PWF, D’Agostino R Sr, Ohman EM, Ro¨ther J, Liau CS,
Hirsch AT, Mas JL, Ikeda Y, Pencina MJ, Goto S. One-year cardiovascular event rates
in outpatients with atherothrombosis. JAMA 2007;297:1197–1206.
10. Criqui MH, Langer RD, FronekA, FeigelsonHS, Klauber MR, McCann TJ, Browner D.
Mortalityover a period of 10 years in patients with peripheral arterial disease. NEngl J
Med 1992;326:381–386.
11. Hirsch AT, Criqui MH, Treat-Jacobson D, Regensteiner JG, Creager MA, Olin JW,
Krook SH, Hunninghake DB, Comerota AJ, Walsh ME, McDermott MM,
Hiatt WR. Peripheral arterial disease detection, awareness, and treatment in
primary care. JAMA 2001;286:1317–1324.
12. Aboyans V, Criqui MH, Abraham P, Allison MA, Creager MA, Diehm C, Fowkes FG,
Hiatt WR, Jo¨nsson B, Lacroix P, Marin B, McDermott MM, Norgren L, Pande RL,
Preux PM, Stoffers HE, Treat-Jacobson D; American Heart Association Council
on Peripheral Vascular Disease; Council on Epidemiology and Prevention; Council
on Clinical Cardiology; Council on Cardiovascular Nursing; Council on Cardiovas-
cular Radiology and Intervention, and Council on Cardiovascular Surgery and Anes-
thesia. Measurement and interpretation of the ankle-brachial index: a scientific
statement from the American Heart Association. Circulation. 2012;126:2890–2909.
13. Gruentzig AR, Hopff H. Perkutane Rekanalisation chronischer arterieller Verschluss
mit einem neuen Dilatationkatheter. Dtsch Med Wochenschr 1974;99:2502–2505.
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Table 5 Measures to increase awareness for
non-coronary atherosclerosis
Targets Measures to increase awareness
Public Public campaigns in analogy to NIH, VDF campaigns
at European-national-, regional-community
levels
General
practioners
Spread the message that LEAD and multivessel
disease are more prevalent than actually
perceived by the medical community
Organize ABI courses
Reimbursement for ABI measurement by GPs
Cardiologists Enhance graduate and postgraduate teaching in
non-coronary atherosclerosis
Spread existent Guidelines on LEAD
Promote RCTs and survey on management of
LEAD at European level
Industry Involvement in public, GPs and specialists
awareness and prevention campaigns
VDF, vascular diseases foundation.
Non-coronary atherosclerosis 1119
14. Shadman R, Criqui MH, Bundens WP, Fronek A, Denenberg JO, Gamst AC,
McDermott MM. Subclavian artery stenosis: prevalence, risk factors, and association
with cardiovascular diseases. J Am Coll Cardiol. 2004;44:618–623.
15. Quyyumi AA. Prognostic value of endothelial function. Am J Cardiol 2003;91:
19H–24H.
16. Brunner H, Cockcroft JR, Deanfield J, Donald A, Ferrannini E, Halcox J, Kiowski W,
Lu¨scher TF, Mancia G, Natali A, Oliver JJ, Pessina AC, Rizzoni D, Rossi GP, Salvetti A,
Spieker LE, Taddei S, Webb DJ. Endothelial function and dysfunction. Part II: associ-
ation with cardiovascular risk factors and diseases. J Hypertens 2005;23:233–246.
17. Lanzino G, Rabinstein AA, Brown RD Jr. Treatment of carotid artery stenosis:
medical therapy, surgery, or stenting?. Mayo Clin Proc 2009;84:362–387.
18. Endarterectomy forasymptomatic carotid artery stenosis: Executive Committee for
the Asymptomatic Carotid Atherosclerosis Study. JAMA 1995;273:1421–1428.
19. Longstreth WT Jr, Shemanski L, Lefkowitz D, O’Leary DH, Polak JF, Wolfson SK.
Asymptomatic internal carotid artery stenosis defined by ultrasound and the risk
of subsequent stroke in the elderly: the Cardiovascular Health Study. Stroke 1998;
29:2371–2376.
20. Lorenz MW, Markus HS, Bots ML, Rosvall M, Sitzer M. Prediction of clinical cardio-
vascular events with carotid intima-media thickness: a systematic review and
meta-analysis. Circulation 2007;115:459–467.
21. Cai J, HatsukamiTS, FergusonMS, Kerwin WS, Saam T, Chu B, Takaya N, PolissarNL,
Yuan C. In vivo quantitative measurement of intact fibrous cap and lipid-rich necrotic
core size in atherosclerotic carotid plaque: comparison of high-resolution,
contrast-enhanced magnetic resonance imaging and histology. Circulation 2005;
112:3437–3444.
22. PoliA,Tremoli E, ColomboA, Sirtori M,Pignoli P, Paoletti R.Ultrasonographicmeas-
urement of the common carotid artery wall thickness in hypercholesterolemic
patients: a new model for the quantitation and follow-up of preclinical atheroscler-
osis in living human subjects. Atherosclerosis 1988;70:253–226.
23. Virmani R, Ladich ER, Burke AP, Kolodgie FD. Histopathology of carotid atheroscler-
otic disease. Neurosurgery. 2006;59:S219–S227.
24. Molloy J, Markus HS. Asymptomatic embolization predicts stroke and TIA risk in
patients with carotid artery stenosis. Stroke 1999;30:1440–1443.
25. Dean N, Shuaib A. Transient ischaemic attacks: unstable, treatable, neglected. The
Lancet 2007;370:1398–1400.
26. CortiR, Fuster V, FayadZA, WorthleySG, HelftG, Smith D, Weinberger J, Wentzel J,
Mizsei G, Mercuri M, Badimon JJ. Lipid lowering by simvastatin induces regression of
human atherosclerotic lesions: two years’ follow-up by high-resolution non-invasive
magnetic resonance imaging. Circulation 2002;106:2884–2887.
27. Strandness DE. Extracranial vessels. Ultrasound Med Biol. 2000;26:S97–S98.
28. Biasi GM, Froio A, Diethrich EB, Galimberti S, Mingazzini P, Nicolaides AN, Griffin M,
Raithel D, Reid DB, Valsecchi MG. Carotid Plaque Echolucency Increases the Risk of
Stroke in Carotid Stenting: The Imaging in Carotid Angioplasty and Risk of Stroke
(ICAROS) Study. Circulation 2004;110:756–762.
29. Staub D, Schinkel AF, Coll B, Coli S, van der Steen AF, Reed JD, Krueger C,
Thomenius KE, Adam D, Sijbrands EJ, ten Cate FJ, Feinstein SB. Contrast-enhanced
ultrasound imaging of the vasa vasorum: from early atherosclerosis to the identifica-
tion of unstable plaques. J Am Coll Cardiol Cardiovasc Imaging. 2010;3:761–771.
30. Fuster V, Fayad ZA, Moreno PR, Poon M, Corti R, Badimon JJ. Atherothrombosis and
high-risk plaque: part II: approaches by noninvasive computed tomographic/magnet-
ic resonance imaging. J Am Coll Cardiol 2005;46:1209–1218.
31. Bianda N, Di Valentino M, Pe´riat D, Segatto JM, Oberson M, Moccetti M, Sudano I,
Santini P, Limoni C, FroioA, Stuber M,CortiR,GallinoA,WyttenbachR. Progression
of human carotid and femoral atherosclerosis: a prospective follow-up studyby mag-
netic resonance vessel wall imaging. Eur Heart J. 2012;33:230–237.
32. Izquierdo-Garcia D, Davies JR, Graves MJ, Rudd JH, Gillard JH, Weissberg PL,
Fryer TD, Warburton EA. Comparison of methods for magnetic resonance-guided
[18-F] fluorodeoxyglucose positron emission tomography in human carotid arter-
ies: reproducibility, partial volume correction, and correlation between methods.
Stroke 2009;40:86–93.
33. Amarenco P, Duyckaerts C, Tzourio C, He´nin D, Bousser MG, Hauw JJ. The preva-
lence of ulcerated plaques in the aortic arch in patients with stroke. N Engl J Med
1992;326:221–225.
34. Meissner I, Khandheria BK, Sheps SG, Schwartz GL, Wiebers DO, Whisnant JP,
Covalt JL, Petterson TM, Christianson TJ, Agmon Y. Atherosclerosis of the aorta:
risk factor, risk marker, or innocent bystander? A prospective population-based
transesophageal echocardiography study. J Am Coll Cardiol 2004;44:1018–1024.
35. Modi KS, Rao VK. Atheroembolic renal disease. J Am Soc Nephrol 2001;12:
1781–1787.
36. Scolari F, Tardanico R, Zani R, Pola A, Viola BF, Movilli E, Maiorca R. Cholesterol
crystal embolism: A recognizable cause of renal disease. Am J Kidney Dis 2000;36:
1089–1109.
37. Diehm N, DiSanto S, Schaffner T. Severe structural damage of the seemingly non-
diseased infrarenal aneurysm neck. J Vasc Surg 2008;48:425–434.
38. Diehm N, Baumgartner I. Determinants of aneurysmal aortic disease. Circulation
2009;119:2134–2135.
39. Lerman LO, Textor SC, Grande JP. Mechanisms of tissue injury in renal artery sten-
osis: Ischemia and beyond. Prog Cardiovasc Dis 2009;52:196–203.
40. Caps MT, Zierler RE, Polissar NL, Bergelin RO, Beach KW, Cantwell-Gab K,
Casadei A, Davidson RC, Strandness DE Jr. Risk of atrophy in kidneys with athero-
sclerotic renal artery stenosis. Kidney Int 1998;53:735–742.
41. Baumgartner I, von Aesch K, Do DD, Triller J, Birrer M, Mahler F. Stent placement in
ostial and nonostial atherosclerotic renal arterial stenoses: a prospective follow-up
study. Radiology 2000;216:498–505.
42. Park JB, Santos JM, Hargreaves BA, Nayak KS, Sommer G, Hu BS, Nishimura DG.
Rapid measurement of renal artery blood flow with ungated spiral phase-contrast
MRI. J Magn Reson Imaging 2005;21:590–595.
43. Uder M, HumkeU. Endovascular therapyof renal artery stenosis: where do we stand
today?. Cardiovasc Intervent Radiol 2005;28:139–147.
44. Brandt LJ, Boley SJ. Intestinal ischemia. In: Feldman M, Friedman LS, Sleisenger MH
(eds), Sleisenger & Fordtran’s gastrointestinal and liver disease, 7th ed. Vol. 2. Philadel-
phia: W.B. Saunders; 2002, p 2321–2340.
45. Horton KM, Fishman EK. CT angiography of the GI tract. Gastrointest Endosc 2002;
55(Suppl):S37–S41.
46. Kasirajan K,O’HaraPJ, Gray BH, Hertzer NR, Clair DG, GreenbergRK, Krajewski LP,
Beven EG, Ouriel K. Chronic mesenteric ischemia: open surgery versus percutan-
eous angioplasty and stenting. J Vasc Surg 2001;33:63–71.
47. White C. Clinical practice. Intermittent claudication. N Engl J Med 2007;356:
1241–1250.
48. Rothwell PM, Coull AJ, Silver LE, Fairhead JF, Giles MF, Lovelock CE, Redgrave JN,
Bull LM, Welch SJ, Cuthbertson FC, Binney LE, Gutnikov SA, Anslow P,
Banning AP, Mant D, Mehta Z. Population-based study of event-rate, incidence,
case fatality, and mortality for all acute vascular events in all arterial territories
(Oxford Vascular Study). The Lancet 2005;366:1773–1783.
49. Fowkes FG, Housley E, Cawood EH, Macintyre CC, Ruckley CV, Prescott RJ. Edin-
burgh Artery Study: prevalence of asymptomatic and symptomatic peripheral arter-
ial disease in the general population. Int J Epidemiol 1991;20:384–392.
50. Baumgartner I, Schainfeld B, Graziani L. Management of peripheral vascular disease.
Ann Rev Med 2005;56:249–272.
51. Dormandy JA, Heeck L, Vig S. The fate of patients with critical leg ischemia. Semin
Vasc Surg 1999;12:142–147.
52. Corti R, Wyttenbach R, Alerci M, Badimon JJ, Fuster V, Gallino A. Images in cardio-
vascular medicine. Effect of percutaneous transluminal angioplasty on severely sten-
otic femoral lesions: in vivo demonstration by noninvasive magnetic resonance
imaging. Circulation 2002;106:1570–1157.
53. Wyttenbach R, Gallino A, Alerci M, Mahler F, Cozzi L, Di Valentino M, Badimon JJ,
Fuster V, Corti R. Effects of percutaneous transluminal angioplasty and endovascular
brachytherapy on vascular remodeling of human femoropopliteal artery by non-
invasive magnetic resonance imaging. Circulation 2004;110:1156–1116.
54. Baumgartner I, Pieczek A, Manor O, Blair R, Kearney M, Walsh K, Isner JM. Consti-
tutive expression of phVEGF165 after intramuscular gene transfer promotes collat-
eral vessel development in patients with critical limb ischemia. Circulation 1998;97:
1114–1123.
55. Isner JM. Cancer and atherosclerosis: the broad mandate of angiogenesis. Circulation
1999;99:1653–1655.
56. McFalls EO, Ward HB, Moritz TE, Goldman S, Krupski WC, Littooy F, Pierpont G,
Santilli S, Rapp J, Hattler B, Shunk K, Jaenicke C, Thottapurathu L, Ellis N, Reda DJ,
Henderson WG. Coronary-artery revascularization before elective major vascular
surgery. N Engl J Med 2004;351:2795–2804.
57. Yusuf S, Hawken S, Oˆunpuu S, Dans T, Avezum A, Lanas F, McQueen M, Budaj A,
Pais P, Varigos J, Lisheng L. Effect of potentially modifiable risk factors associated
with myocardial infarction in 52 countries (the INTERHEART study): case-control
study. Lancet 2004;364:937–952.
58. Aboyans V, Criqui MH, Denenberg JO, Knoke JD, Ridker PM, Fronek A. Risk factors
for progression of peripheral arterial disease in large and small vessels. Circulation
2006;113:2623–2629.
59. Lombardo A, Biasucci LM, Lanza GA, Coli St, Silvestri P, Cianflone D, Liuzzo G,
Burzotta F, Crea F, Maseri A. Inflammation as a possible link between coronary
and carotid plaque instability. Circulation 2004;109:3158–3163.
60. Price JF, Mowbray PI, Lee AJ, Rumley A, Lowe GD, Fowkes FG. Relationship between
smoking and cardiovascular risk factors in the development of peripheral arterial
disease and coronary artery disease: Edinburgh Artery Study. Eur Heart J 1999;20:
344–353.
61. Hooi JD, Stoffers HE, Kester AD, Rinkens PE, Kaiser V, van Ree JW, Knottnerus JA.
Risk factors andcardiovasculardiseases associatedwith asymptomatic peripheral ar-
terial occlusive disease. The Limburg PAOD Study. Peripheral Arterial Occlusive
Disease. Scand J Prim Health Care 1998;16:177–182.
62. Yusuf S, Sleight P, Pogue J, Bosch J, Davies R, Dagenais G. Effects of an angiotensin-
convertingenzyme inhibitor, ramipril, on cardiovascular events in high-risk patients
A. Gallino et al.1119a
The Heart Outcomes Prevention Evaluation Study Investigators. N Engl J Med 2000;
342:145–153.
63. Criqui MH, Denenberg JO, Langer RD, Fronek A. The epidemiology of peripheral
arterial disease: importance of identifying the population at risk. Vasc Med 1997;2:
221–226.
64. Ness J, Aronow WS. Prevalence of coexistence of coronary artery disease, ischemic
stroke, and peripheral arterial disease in older persons, mean age 80 years, in an aca-
demic hospital-based geriatrics practice. J Am Geriatr Soc 1999;47:1255–1256.
65. Alexandrova NA, Gibson WC, Norris JW, Maggisano R. Carotid artery stenosis in
peripheral vascular disease. J Vasc Surg 1996;23:645–649.
66. Cheng SW, Wu LL, Ting AC, Lau H, Wong J. Screening for asymptomatic carotid
stenosis in patients with peripheral vascular disease: a prospective study and risk
factor analysis. Cardiovasc Surg 1999;7:303–309.
67. Long TH, Criqui MH, Vasilevskis EE, Denenberg JO, Klauber MR, Fronek A. The cor-
relation between the severity of peripheral arterial disease and carotid occlusive
disease. Vasc Med 1999;4:135–142.
68. Criqui MH, Fronek A, Klauber MR, Barrett-Connor E, Gabriel S. The sensitivity, spe-
cificity, and predictive value of traditional clinical evaluation of peripheral arterial
disease: results from noninvasive testing in a defined population. Circulation 1985;
71:516–522.
69. Leng GC, Lee AJ, Fowkes FG, Whiteman M, Dunbar J, Housley E, Ruckley CV. Inci-
dence, natural history and cardiovascular events in symptomatic and asymptomatic
peripheral arterial disease in the general population. Int J Epidemiol 1996;25:
1172–1181.
70. Newman AB, Sutton-Tyrrell K, Vogt MT, Kuller LH. Morbidity and mortality in
hypertensive adults with a low ankle/arm blood pressure index. JAMA 1993;270:
487–489.
71. Zheng ZJ, Sharrett AR, Chambless LE, Rosamond WD, Nieto FJ, Sheps DS, Dobs A,
Evans GW, Heiss G. Associations of ankle-brachial index with clinical coronary heart
disease, strokeandpreclinical carotid andpopliteal atherosclerosis: theAtheroscler-
osis Risk in Communities (ARIC) Study. Atherosclerosis 1997;131:115–125.
72. Van der Worp HB, Van Gijn J. Acute ischemic stroke. N Engl J Med 2007;357:
572–579.
73. Watanabe M, Kimura K, Iguchi Y, Shibazaki K, Urabe T, Hattori N. Peripheral arterial
atherosclerosis in patients with extracranial, not intracranial, arterial stenosis. Intern
Med. 2010;49:1515–1519.
74. Topakian R, Nanz S, Rohrbacher B, Koppensteiner R, Aichner FT; OECROSS Study
Group. High prevalence of peripheral arterial disease in patients with acute ischae-
mic stroke. Cerebrovasc Dis. 2010;29:248–254.
75. Hertzer NR, Young JR, Kramer JR, Phillips DF, deWolfe VG, Ruschhaupt WF III,
Beven EG. Routine coronary angiography prior to elective aortic reconstruction:
results of selective myocardial revascularization in patients with peripheral vascular
disease. Arch Surg 1979;114:1336–1344.
76. Mesh CL, Cmolik BL, Van Heekeren DW, Whittlesey D, Graham LM, Geha AS,
Bowlin SJ. Coronary bypass in vascular patients: a relatively high-risk procedure.
Ann Vasc Surg 1997;11:612–619.
77. Ix JH, Criqui MH. Epidemiologyand diagnosis of peripheral arterial disease in patients
with chronic kidney disease. Adv Chronic Kidney Dis 2008;15:378–383.
78. MahoneyEM,Wang K,CohenDJ,Hirsch AT, Alberts MJ, Eagle K,MosseF, Jackson JD,
Steg PG, Bhatt DL. One-year costs in patients with a history of or at risk for ather-
othrombosis in the United States. Circ Cardiovasc Qual Outcomes 2008;1:38–45.
79. MahoneyEM,Wang K,Keo HH,Duval S, SmolderenKG, CohenDJ, StegG,BhattDL,
Hirsch AT. Reduction of atherothrombosis for continued health (REACH) registry
investigators. Circ Cardiovasc Qual Outcomes 2010;3:642–651.
80. Smolderen KG, Wang K, de Pouvourville G, Bru¨ggenju¨rgen B, Ro¨ther J, Zeymer U,
Parhofer KG, Steg PG, Bhatt DL, Magnuson EA; REACH Registry Investigators.
Two-year vascular hospitalisation rates and associated costs in patients at risk of
atherothrombosis in France and Germany: highest burden for peripheral arterial
disease. Eur J Vasc Endovasc Surg 2012;43:198–207.
81. Brevetti G, Chiariello M. Peripheral arterial disease: the magnitude of the problem
and its socioeconomic impact. Curr Drug Targets Cardiovasc Haematol Disord. 2004;
4:199–208.
82. Sigvant B, Henriksson M, Lundin F, Wahlberg E. Asymptomatic peripheral arterial
disease: is pharmacological prevention of cardiovascular risk cost-effective?. Eur J
Cardiovasc Prev Rehabil. 2011;18:254–261.
83. Moriarty JP, Murad MH, Shah ND, Prasad C, Montori VM, Erwin PJ, Forbes TL,
Meissner MH, Stoner MC. Society for vascular surgery committee on comparative
effectiveness collaborators: a systematic review of lower extremity arterial revascu-
larization economic analyses. J Vasc Surg 2011;54:1131–1144.
84. Corti R, Ferrari C, Roberti M, Alerci M, Pedrazzi PL, Gallino A. spiral computed tom-
ography: a novel diagnostic approach for investigation of the extracranial cerebral
arteries and its complementary role in duplex ultrasonography. Circulation 1998;
98:984–989.
Non-coronary atherosclerosis 1119b
